Canadian firm produces insulin in biotech plants

04/4/2007 | BBC

The CEO of SemBioSys Genetics says his company has found a way to make insulin by implanting a human gene into safflower seeds, and believes SemBioSys may be the first company to market a plant-based pharmaceutical. CEO Andrew Baum said one large farm growing the biotech safflower could satisfy the global demand for insulin and lower the price of the drug.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX